Anti-TIM-3 + Anti-PD-1 Antibodies for Liver Cancer

Recruiting in Palo Alto (17 mi)

+1 other location

Overseen byJared D. Acoba

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: University of Hawaii

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?This trial is testing two drugs, cobolimab and dostarlimab, to help the immune system fight advanced or spreading liver cancer. The drugs work by blocking proteins that allow cancer cells to hide from the immune system, making it easier for the body to attack them.

Eligibility Criteria

Adults with advanced liver cancer who haven't had systemic therapy can join this trial. They need good kidney function, controlled hepatitis if present, and at least one measurable tumor. They must not have severe lung conditions or be on recent immunosuppressants, live vaccines, or have other active cancers (with some exceptions). Pregnant women are excluded.

Inclusion Criteria

My liver cancer diagnosis was confirmed through lab tests.

My liver disease is mild to moderate.

Participant must be able to understand the study procedures and agree to participate in the study by providing written informed consent

+14 more

Exclusion Criteria

I have had an organ or bone marrow transplant.

Psychiatric illness/social situations that would limit compliance with study requirements

I have been treated with drugs targeting PD-1, PD-L1, or TIM-3.

+15 more

Participant Groups

The trial is testing the combination of two immune system-boosting drugs: TSR-022 (cobolimab) and TSR-042 (dostarlimab), to see if they help the body fight liver cancer better together than existing treatments.

1Treatment groups

Experimental Treatment

Group I: TSR-022 (Cobolimab) and TSR-042 (Dostarlimab)Experimental Treatment1 Intervention

Patients receive TSR-022 (cobolimab, TIM-3 binding antibody) and TSR-042 (dostarlimab, PD-1 binding antibody) via IV day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.